Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marion R Munk

Showing results (91-100 of 159) with videos related to

Pageof 16
Sort By:
The British Journal of Ophthalmology|August 6, 2013
Systematic correlation of morphologic alterations and retinal function in eyes with uveitis-associated cystoid macular oedema during development, resolution and relapseMarion R Munk, Christopher G Kiss, Irene Steiner, et al.
The British Journal of Ophthalmology|August 22, 2015
New associations of classic acute macular neuroretinopathyMarion R Munk, Lee M Jampol, Eduardo Cunha Souza, et al.
Ophthalmology. Retina|July 3, 2026
Effect of key baseline disease characteristics on aflibercept 8 mg dosing interval extension: A post hoc 96-week analysis of PULSARJustus G Garweg, Varun Chaudhary, Xin Zhang, et al.
American Journal of Ophthalmology|July 30, 2013
One year follow-up of functional recovery in neovascular AMD during monthly anti-VEGF treatmentMarion R Munk, Christopher Kiss, Wolfgang Huf, et al.
Ophthalmology. Retina|May 10, 2021
Machine Learning Can Predict Anti-VEGF Treatment Demand in a Treat-and-Extend Regimen for Patients with Neovascular AMD, DME, and RVO Associated Macular EdemaMathias Gallardo, Marion R Munk, Thomas Kurmann, et al.
Eye (London, England)|December 2, 2022
Transforming ophthalmology in the digital century-new care models with added value for patientsLivia Faes, Peter M Maloca, Katja Hatz, et al.
Ophthalmology|June 17, 2020
Macular Atrophy Incidence and Progression in Eyes with Neovascular Age-Related Macular Degeneration Treated with Vascular Endothelial Growth Factor Inhibitors Using a Treat-and-Extend or a Pro Re Nata Regimen: Four-Year Results of the MANEX StudyKimberly L Spooner, Samantha Fraser-Bell, Mariano Cozzi, et al.
Ophthalmology|October 18, 2019
Macular Atrophy in Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial Comparing Ranibizumab and Aflibercept (RIVAL Study)Mark C Gillies, Alex P Hunyor, Jennifer J Arnold, et al.
Eye (London, England)|January 30, 2026
SPECTRUM: early clinical experience from the first global real-world study of aflibercept 8 mg in patients with neovascular age-related macular degenerationClare Bailey, Clemens Lange, Varun Chaudhary, et al.
Frontiers in Medicine|October 9, 2023
Herpetic anterior uveitis following COVID-19 vaccines: a case seriesMuriel Ott, Thanoosha Nagamany, Souska Zandi, et al.
Pageof 16

Showing results (91-100 of 159) with videos related to

Sort By:
Pageof 16
The British Journal of Ophthalmology|August 6, 2013
Systematic correlation of morphologic alterations and retinal function in eyes with uveitis-associated cystoid macular oedema during development, resolution and relapseMarion R Munk, Christopher G Kiss, Irene Steiner, et al.
The British Journal of Ophthalmology|August 22, 2015
New associations of classic acute macular neuroretinopathyMarion R Munk, Lee M Jampol, Eduardo Cunha Souza, et al.
Ophthalmology. Retina|July 3, 2026
Effect of key baseline disease characteristics on aflibercept 8 mg dosing interval extension: A post hoc 96-week analysis of PULSARJustus G Garweg, Varun Chaudhary, Xin Zhang, et al.
American Journal of Ophthalmology|July 30, 2013
One year follow-up of functional recovery in neovascular AMD during monthly anti-VEGF treatmentMarion R Munk, Christopher Kiss, Wolfgang Huf, et al.
Ophthalmology. Retina|May 10, 2021
Machine Learning Can Predict Anti-VEGF Treatment Demand in a Treat-and-Extend Regimen for Patients with Neovascular AMD, DME, and RVO Associated Macular EdemaMathias Gallardo, Marion R Munk, Thomas Kurmann, et al.
Eye (London, England)|December 2, 2022
Transforming ophthalmology in the digital century-new care models with added value for patientsLivia Faes, Peter M Maloca, Katja Hatz, et al.
Ophthalmology|June 17, 2020
Macular Atrophy Incidence and Progression in Eyes with Neovascular Age-Related Macular Degeneration Treated with Vascular Endothelial Growth Factor Inhibitors Using a Treat-and-Extend or a Pro Re Nata Regimen: Four-Year Results of the MANEX StudyKimberly L Spooner, Samantha Fraser-Bell, Mariano Cozzi, et al.
Ophthalmology|October 18, 2019
Macular Atrophy in Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial Comparing Ranibizumab and Aflibercept (RIVAL Study)Mark C Gillies, Alex P Hunyor, Jennifer J Arnold, et al.
Eye (London, England)|January 30, 2026
SPECTRUM: early clinical experience from the first global real-world study of aflibercept 8 mg in patients with neovascular age-related macular degenerationClare Bailey, Clemens Lange, Varun Chaudhary, et al.
Frontiers in Medicine|October 9, 2023
Herpetic anterior uveitis following COVID-19 vaccines: a case seriesMuriel Ott, Thanoosha Nagamany, Souska Zandi, et al.
Pageof 16